BE1000967A5 - Compositions d'anticorps monoclonaux humains assurant la protection croisee. - Google Patents

Compositions d'anticorps monoclonaux humains assurant la protection croisee. Download PDF

Info

Publication number
BE1000967A5
BE1000967A5 BE8700093A BE8700093A BE1000967A5 BE 1000967 A5 BE1000967 A5 BE 1000967A5 BE 8700093 A BE8700093 A BE 8700093A BE 8700093 A BE8700093 A BE 8700093A BE 1000967 A5 BE1000967 A5 BE 1000967A5
Authority
BE
Belgium
Prior art keywords
sep
species
antibody
antibodies
composition according
Prior art date
Application number
BE8700093A
Other languages
English (en)
French (fr)
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Application granted granted Critical
Publication of BE1000967A5 publication Critical patent/BE1000967A5/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BE8700093A 1986-02-07 1987-02-06 Compositions d'anticorps monoclonaux humains assurant la protection croisee. BE1000967A5 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82800586A 1986-02-07 1986-02-07
US94449586A 1986-12-19 1986-12-19

Publications (1)

Publication Number Publication Date
BE1000967A5 true BE1000967A5 (fr) 1989-05-30

Family

ID=27125154

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8700093A BE1000967A5 (fr) 1986-02-07 1987-02-06 Compositions d'anticorps monoclonaux humains assurant la protection croisee.

Country Status (28)

Country Link
US (2) US5717071A (enExample)
JP (1) JP2645343B2 (enExample)
KR (1) KR870007697A (enExample)
CN (1) CN87102167A (enExample)
AT (1) AT398781B (enExample)
BE (1) BE1000967A5 (enExample)
CA (1) CA1339013C (enExample)
CH (1) CH672072A5 (enExample)
DE (1) DE3703711A1 (enExample)
DK (1) DK63187A (enExample)
ES (1) ES2009140A6 (enExample)
FI (1) FI94489C (enExample)
FR (1) FR2595946B1 (enExample)
GB (1) GB2186592B (enExample)
GR (1) GR870194B (enExample)
HK (1) HK21795A (enExample)
HU (1) HU203583B (enExample)
IE (1) IE59627B1 (enExample)
IL (1) IL81370A (enExample)
IT (1) IT1207589B (enExample)
LU (1) LU86761A1 (enExample)
MX (1) MX9203629A (enExample)
NL (1) NL8700286A (enExample)
NO (1) NO176924C (enExample)
NZ (2) NZ233920A (enExample)
OA (1) OA08477A (enExample)
PT (1) PT84258B (enExample)
SE (1) SE468747B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
DE3925161A1 (de) * 1989-03-15 1990-09-27 Boehringer Mannheim Gmbh Monoklonale, gegen eca gerichtete antikoerper und ihre verwendung
AU5675790A (en) * 1989-05-09 1990-11-29 Cetus Corporation Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
DE69329642T3 (de) * 1992-03-19 2009-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
EP0680337A4 (en) * 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
ATE474849T1 (de) * 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
CA2694466A1 (en) * 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
US8444983B2 (en) * 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
AU2011336366B2 (en) 2010-12-03 2016-05-12 Sanofi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105804A2 (en) * 1982-09-30 1984-04-18 The University Of Rochester Human monoclonal antibodies against bacterial toxins
WO1985001659A1 (en) * 1983-10-14 1985-04-25 Centocor, Inc. Monoclonal antibodies against endotoxin of gram-negative bacteria
EP0163493A2 (en) * 1984-05-25 1985-12-04 Genetic Systems Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105804A2 (en) * 1982-09-30 1984-04-18 The University Of Rochester Human monoclonal antibodies against bacterial toxins
WO1985001659A1 (en) * 1983-10-14 1985-04-25 Centocor, Inc. Monoclonal antibodies against endotoxin of gram-negative bacteria
EP0163493A2 (en) * 1984-05-25 1985-12-04 Genetic Systems Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEDERATION PROCEEDINGS (US), vol. 44, no. 4, 1985, page 1328, résumé no. 5366; E. HORNBERGER et al.: "Human monoclonal antibodies against gram-negative bacteria" *

Also Published As

Publication number Publication date
FI870502L (fi) 1987-08-08
NL8700286A (nl) 1987-09-01
GB2186592B (en) 1990-08-01
FI94489B (fi) 1995-06-15
IL81370A (en) 1991-06-30
GB8702689D0 (en) 1987-03-11
MX9203629A (es) 1992-07-01
OA08477A (fr) 1988-07-29
NO870476L (no) 1987-08-10
JPS62270535A (ja) 1987-11-24
GB2186592A (en) 1987-08-19
NZ219187A (en) 1990-12-21
DK63187D0 (da) 1987-02-06
PT84258B (pt) 1989-09-14
IT8719292A0 (it) 1987-02-06
US5717071A (en) 1998-02-10
JP2645343B2 (ja) 1997-08-25
IL81370A0 (en) 1987-08-31
SE8700467L (sv) 1987-08-08
DE3703711C2 (enExample) 1993-06-24
AT398781B (de) 1995-01-25
LU86761A1 (fr) 1987-09-15
PT84258A (en) 1987-03-01
CH672072A5 (enExample) 1989-10-31
NO176924B (no) 1995-03-13
DE3703711A1 (de) 1987-09-24
NO870476D0 (no) 1987-02-06
HUT46062A (en) 1988-09-28
GR870194B (en) 1987-06-10
DK63187A (da) 1987-08-08
IE59627B1 (en) 1994-03-09
CN87102167A (zh) 1988-02-03
US5837541A (en) 1998-11-17
FI94489C (fi) 1995-09-25
HU203583B (en) 1991-08-28
IT1207589B (it) 1989-05-25
KR870007697A (ko) 1987-09-21
NZ233920A (en) 1990-12-21
CA1339013C (en) 1997-03-25
SE468747B (sv) 1993-03-15
FI870502A0 (fi) 1987-02-06
ES2009140A6 (es) 1989-09-01
IE870320L (en) 1987-08-07
FR2595946A1 (fr) 1987-09-25
FR2595946B1 (fr) 1991-10-04
HK21795A (en) 1995-02-24
NO176924C (no) 1995-06-21
SE8700467D0 (sv) 1987-02-06
ATA26287A (de) 1994-06-15

Similar Documents

Publication Publication Date Title
LU86761A1 (fr) Compositions d'anticorps monoclonaux humains assurant la protection croisee
FI89278C (fi) Metod foer framstaellning av monoklonal human antikropp mot serotypiska lipopolysackariddeterminanter pao gramnegativa bakterier
Archambaud et al. Enterococcus faecalis: an overlooked cell invader
Woods et al. Interaction of insulin with Pseudomonas pseudomallei
JPH02283294A (ja) ヒトモノクローナル抗体
FR2593826A1 (fr) Anticorps monoclonaux a reactivite et a protectivite croisees vis-a-vis des serotypes de p. aeruginosa
JPS5989697A (ja) ポリリボシルリビト−ルホスフエ−トと反応性のヒトモノクロ−ナル抗体
US4970070A (en) Protective monoclonal antibody compositions for infections due to group B streptococcus
EP0341684A2 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
JP4002187B2 (ja) 抗ふけ菌免疫抗体及びその用途
LU86938A1 (fr) Anticorps monoclonaux contre les flagelles de pseudomonas aeruginosa
KR910004868B1 (ko) 인체 단일 클론항체 및 그것을 활성성분으로 함유하는 감염증의 예방 및 치료용 약학적 제제
Shirmohammadpour et al. Investigation of the effect of anti-PIA/PNAG antibodies on biofilm formation in Escherichia coli
BE1001844A4 (fr) Anticorps monoclonal humain contre pseudomonas aeruginosa, sa production et son application.
ROSEBURY The Aerobic Non-hemolytic Streptococci: a Critical Review of their Characteristics and Pathogenicity with Special Reference to the Human Mouth and to Subacute Bacterial Endocarditis
Piot et al. Bacterial endocarditis due to Cardiobacterium hominis
DE3745019C2 (de) Kreuz-schützende monoklonale Humanantikörper
Ricci et al. Protective activity of a murine monoclonal antibody against acute and chronic experimental infection with type IV group B streptococcus
Wertheim et al. Endocarditis Caused by Nontypeable Streptococcus pneumoniae
Von Hunolstein et al. Adherence of S. bovis to adult buccal epithelial cells.
Owhe-Ureghe Experimental Protective Effects of Yersinia Anti-Antibodies in Mice
McClure Effect on Oral Streptococci of Exposure to Penicillin and Its Relevance in Infective Endocarditis Prophylaxis
Sulakvelidze et al. 14 Bacteriophage Therapy
KR20200075980A (ko) 항생제 내성을 갖는 클렙시엘라 속의 균을 용균하는 신규한 박테리오파지
JPS61152280A (ja) 抗緑膿菌ヒト抗体を産生する形質転換細胞及びその製造法並びにその使用方法

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: GENETIC SYSTEMS CORP.

Effective date: 19990228